{
    "organizations": [],
    "uuid": "e361c37c03cd6ed36864a66284c0d5c512ce9f3d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cytokinetics-qtrly-net-loss-per-sh/brief-cytokinetics-qtrly-net-loss-per-share-0-75-idUSASB0C61J",
    "ord_in_thread": 0,
    "title": "BRIEF-Cytokinetics Qtrly Net Loss Per Share $0.75",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 15 (Reuters) - Cytokinetics Inc:\n* CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS\n* ‍ENROLLMENT IN GALACTIC-HF ON TRACK UNDER COLLABORATION WITH AMGEN; FINALIZING PLANS FOR SECOND PHASE 3 CLINICAL TRIAL IN 2018​\n* ‍COMPANY ANTICIPATES CASH REVENUE WILL BE IN RANGE OF $17 TO $23 MILLION FOR 2018​\n* QTRLY NET LOSS PER SHARE $0.75 * Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S\n* FY2018 REVENUE VIEW $25.6 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-16T05:05:00.000+02:00",
    "crawled": "2018-02-16T16:45:45.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "cytokinetics",
        "inc",
        "cytokinetics",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "track",
        "collaboration",
        "amgen",
        "finalizing",
        "plan",
        "second",
        "phase",
        "clinical",
        "trial",
        "anticipates",
        "cash",
        "revenue",
        "range",
        "million",
        "qtrly",
        "net",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "fy2018",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}